Key Drivers
- High Gross Margin
- Persistent Net Loss
- Rich Valuation
AIAI Summary
ARQT has shifted from a pure dermatology launch story to a high-stakes execution test for turning ZORYVE into a durable cash-generating franchise, with strong margins and positive operating cash flow supporting the thesis but the stock still hinging on sustained adoption and successful conversion of pediatric/infant catalysts before valuation pressure intensifies.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Gross Margin
- •Persistent Net Loss
- •Rich Valuation
ARQT combines strong gross margins and solid liquidity with persistent losses, weaker recent cash generation, and elevated valuation multiples, making the stock fundamentally stretched despite a healthy balance sheet.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed support
- •Range capped
Over the last month, ARQT remains in a clear downtrend after a sharp break from the mid-$24s to about $20.66, with $20.66-$20.69 acting as near-term support and $23-$24 still capping rallies.
Sharp drop from the mid-$24s to around $20.66 on 2026-05-06 to 2026-05-07 signaled support failure and seller control
Sentiment & News
Key News Insights:
- •Pediatric support
- •Infant expansion
- •Revenue growth
Arcutis posted strong Q1 ZORYVE growth, won pediatric guideline support, and moved to expand use in infants while reaffirming 2026 revenue guidance.
The updates reinforce ARQT's commercial momentum and broaden ZORYVE's growth runway, supporting a positive near-term outlook for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings